Calendar

«« Nov 2007 »»
S M T W T F S
       
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18 19 20 21 22 23 24
25 26 27 28 29 30

Search Box


HealthCentral Top Site Award

IBS Tales Hope Award

Ai in the media

Reuters:
Research links asthma and post-traumatic stress disorder

WESH-2, Orlando FL:

Fox Business:
Acne drug’s link to depression

LinkBlog

Most People are Optimists - Except for Lawyers

The Army's Post Traumatic Stress Disorder and Mild Traumatic Brain Injury (PTSD/MTBI) Chain Teaching Program

Cannabis, the mind and society: the hash realities (PDF - free reg. req'd)

The Role of Cognitive and Behavioral Therapies in the Treatment of Insomnia

  More

Contact

Mailing List

RSS Feeds








Translation

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

recommended links

Depression is Real's Down & Up Show
      Weekly audio-casts from the
      Depression Is Real Coalition

we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 1,008,070
since: 14 May 2006

Admin console

Log-In

My Blog    My Profile

Leave Message

Add as neighbors






Blogion.com

Blog Flux Directory



Blogarama - The Blogs Directory

blog search directory

BlogTagstic - Blog Directory

Find Blogs in the Blog Directory



LS Blogs

Top Health Sites





Health Blogs - Blog Top Sites

Bloggapedia - Find It!

Cannabinoid receptor antagonists increase quit smoking success rate, lessen weight gain

« H E » email
posted Thursday, 2 August 2007

Using selective cannabinoid 1 (CB1) receptor antagonists such as rimonabant (Acomplia® at a dose of 20 mg per day can help people quit smoking, can help them to remain abstinent, and can help prevent the weight gain that so often accompanies attempts at stopping smoking. The lower dose of 5mg, however, was not shown to be effective, according to a Cochrane Systematic Review.

Smoking tobacco sends nicotine into the blood stream, and this chemical disrupts the endocannabinoid system, part of the hormonal control mechanism in the brain that controls energy balance and food intake. Over time the body alters the nature of its energy mechanism to compensate for this effect. Stopping smoking removes the nicotine and once again disturbs the mechanism, adding to the withdrawal symptoms and leaving a person prone to put on weight.

One potential way of preventing this is to take a drug that blocks the receptor that is involved in nicotine's action in the brain - the cannabinoid 1 receptor. These CB1 receptor antagonists could therefore form part of a therapeutic program aimed at helping individuals quit smoking, although this drug has not yet been approved as a smoking cessation treatment in the USA or in Europe.

To see whether there was evidence that these receptor antagonists work two Cochrane Researchers, Kate Cahill who works at the Department of Primary Care in the University of Oxford and Michael Ussher of St George's, University of London, searched the published and unpublished literature for relevant research projects. They found three trials that involved a total of 1567 smokers and 1661 people who had recently quit smoking. Analysing the data showed that the effect of the drug depended on the dose used:
  • People given 20 mg rimonabant increased by 50% their odds of remaining abstinent compared with those on placebo. Smokers who had quit while using 20mg rimonabant increased by 50% their odds of staying abstinent if they continued taking either 5mg or 20mg rimonabant, compared with those who moved to placebo treatment after quitting.


  • People who wanted to quit appeared to gain no benefit from 5 mg rimonabant treatment. Furthermore the people who did manage to quit using this lower dose were equally likely to remain abstinent whether they continued with rimonabant treatment or moved to a placebo.


  • Weight gain appeared to be significantly lower in people who quit while using 20 mg rimonabant than those taking either 5 mg rimonabant or placebo. The differences in weight between the groups appeared to be maintained through longest follow-up. This beneficial effect was more evident in overweight or obese smokers than in those of normal weight.

"From the preliminary data that we found it appears that 20mg rimonabant may significantly increase a person's likelihood of quitting and may also reduce the amount of weight that they gain," says Cahill.


Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005353   [Full review]

tags:  

links: digg this    del.icio.us    technorati    reddit